Tags

Type your tag names separated by a space and hit enter

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.
Clin Res Cardiol. 2020 May; 109(5):531-538.CR

Abstract

BACKGROUND

Studies have reminded that cardiovascular metabolic comorbidities made patients more susceptible to suffer 2019 novel corona virus (2019-nCoV) disease (COVID-19), and exacerbated the infection. The aim of this analysis is to determine the association of cardiovascular metabolic diseases with the development of COVID-19.

METHODS

A meta-analysis of eligible studies that summarized the prevalence of cardiovascular metabolic diseases in COVID-19 and compared the incidences of the comorbidities in ICU/severe and non-ICU/severe patients was performed. Embase and PubMed were searched for relevant studies.

RESULTS

A total of six studies with 1527 patients were included in this analysis. The proportions of hypertension, cardia-cerebrovascular disease and diabetes in patients with COVID-19 were 17.1%, 16.4% and 9.7%, respectively. The incidences of hypertension, cardia-cerebrovascular diseases and diabetes were about twofolds, threefolds and twofolds, respectively, higher in ICU/severe cases than in their non-ICU/severe counterparts. At least 8.0% patients with COVID-19 suffered the acute cardiac injury. The incidence of acute cardiac injury was about 13 folds higher in ICU/severe patients compared with the non-ICU/severe patients.

CONCLUSION

Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19. On the other hand, COVID-19 can, in turn, aggravate the damage to the heart.

Links

PMC Free PDF

Authors+Show Affiliations

Li B
Department of Cardiology, Zibo Central Hospital, Shandong University, No. 10, Sonth Shanghai Road, Zibo, 255000, People's Republic of China. libosubmit@163.com.
Yang J
Department of Cardiology, Zibo Central Hospital, Shandong University, No. 10, Sonth Shanghai Road, Zibo, 255000, People's Republic of China. Binzhou Medical University, No. 346, Guanhai Road, Laishan District, Yantai, 264003, Shandong, People's Republic of China.
Zhao F
Department of Infectious Diseases, No. 4 Hospital of Zibo, No. 210, Shan Quan Road, Zibo, 255000, People's Republic of China.
Zhi L
Department of Allergy, Zibo Central Hospital, Shandong University, No. 10, Sonth Shanghai Road, Zibo, 255000, People's Republic of China.
Wang X
Department of Cardiology, Zibo Central Hospital, Shandong University, No. 10, Sonth Shanghai Road, Zibo, 255000, People's Republic of China.
Liu L
Department of Cardiology, Zibo Central Hospital, Shandong University, No. 10, Sonth Shanghai Road, Zibo, 255000, People's Republic of China.
Bi Z
Department of Cardiology, Zibo Central Hospital, Shandong University, No. 10, Sonth Shanghai Road, Zibo, 255000, People's Republic of China.
Zhao Y
Department of Cardiology, Zibo Central Hospital, Shandong University, No. 10, Sonth Shanghai Road, Zibo, 255000, People's Republic of China. zhaoyunhe@medmail.com.cn.

MeSH

BetacoronavirusCOVID-19Cardiovascular DiseasesChinaCoronavirus InfectionsHumansMetabolic SyndromePandemicsPneumonia, ViralPrevalenceSARS-CoV-2

Pub Type(s)

Journal Article
Meta-Analysis
Review

Language

eng

PubMed ID

32161990

Clinical Trial Links

Independent Predictors on Clinical Outcomes in SARS-CoV2 Patients
Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection
WORLD HEART FEDERATION (WHF) COVID-19 and Cardiovascular Disease Survey
Eucaloric Ketogenic Diet in COVID-19 Cytokine Storm Syndrome
ICU Trial in Critical Ill COVID-19 Patients

Citation

Li, Bo, et al. "Prevalence and Impact of Cardiovascular Metabolic Diseases On COVID-19 in China." Clinical Research in Cardiology : Official Journal of the German Cardiac Society, vol. 109, no. 5, 2020, pp. 531-538.
Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531-538.
Li, B., Yang, J., Zhao, F., Zhi, L., Wang, X., Liu, L., Bi, Z., & Zhao, Y. (2020). Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clinical Research in Cardiology : Official Journal of the German Cardiac Society, 109(5), 531-538. https://doi.org/10.1007/s00392-020-01626-9
Li B, et al. Prevalence and Impact of Cardiovascular Metabolic Diseases On COVID-19 in China. Clin Res Cardiol. 2020;109(5):531-538. PubMed PMID: 32161990.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. AU - Li,Bo, AU - Yang,Jing, AU - Zhao,Faming, AU - Zhi,Lili, AU - Wang,Xiqian, AU - Liu,Lin, AU - Bi,Zhaohui, AU - Zhao,Yunhe, Y1 - 2020/03/11/ PY - 2020/02/17/received PY - 2020/03/02/accepted PY - 2020/3/13/pubmed PY - 2020/4/29/medline PY - 2020/3/13/entrez KW - 2019-nCoV KW - COVID-19 KW - Cardiac injury KW - Cardiovascular metabolic diseases SP - 531 EP - 538 JF - Clinical research in cardiology : official journal of the German Cardiac Society JO - Clin Res Cardiol VL - 109 IS - 5 N2 - BACKGROUND: Studies have reminded that cardiovascular metabolic comorbidities made patients more susceptible to suffer 2019 novel corona virus (2019-nCoV) disease (COVID-19), and exacerbated the infection. The aim of this analysis is to determine the association of cardiovascular metabolic diseases with the development of COVID-19. METHODS: A meta-analysis of eligible studies that summarized the prevalence of cardiovascular metabolic diseases in COVID-19 and compared the incidences of the comorbidities in ICU/severe and non-ICU/severe patients was performed. Embase and PubMed were searched for relevant studies. RESULTS: A total of six studies with 1527 patients were included in this analysis. The proportions of hypertension, cardia-cerebrovascular disease and diabetes in patients with COVID-19 were 17.1%, 16.4% and 9.7%, respectively. The incidences of hypertension, cardia-cerebrovascular diseases and diabetes were about twofolds, threefolds and twofolds, respectively, higher in ICU/severe cases than in their non-ICU/severe counterparts. At least 8.0% patients with COVID-19 suffered the acute cardiac injury. The incidence of acute cardiac injury was about 13 folds higher in ICU/severe patients compared with the non-ICU/severe patients. CONCLUSION: Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19. On the other hand, COVID-19 can, in turn, aggravate the damage to the heart. SN - 1861-0692 UR - https://www.unboundmedicine.com/medline/citation/32161990/Prevalence_and_impact_of_cardiovascular_metabolic_diseases_on_COVID_19_in_China_ DB - PRIME DP - Unbound Medicine ER -